[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pediatric-osteosarcoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pediatric-osteosarcoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100659931","phase-3-fight-osteosarcoma-through-european-research-evolving-study-platform-from-diagnosis-to-relapse-100659931",false,"NCT07871864","Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse","FOSTER Evolving Study Platform","FOSTER","REGISTRATION in FOSTER-Evolving study platfom, Part-1:\n\nInclusion Criteria :\n\n1. Newly diagnosed, biopsy-proven, high-grade osteosarcoma,\n2. Patient considered medically fit to receive systemic treatment,\n3. Planned systemic therapy according to national guidelines and age\n4. Written informed consent from patients or for minor, from their parents\u002F legal representatives, before enrolment and any study-related procedure.\n5. Affiliation to a social insurance or equivalent regimen (if required in the country).\n\nExclusion Criteria:\n\n1\\. Low-grade osteosarcoma, parosteal or periosteal osteosarcoma, small cell osteosarcoma\n\nFOR FOSTER-CabOS RANDOMISATION (part-2) :\n\n1. Patient with a histologically proven and confirmed high-grade osteosarcoma, according to the criteria described in the last World Health Organization (WHO) classification of Soft Tissue and Bone Tumours, after the exclusion of all potential differential diagnoses, either by local pathologists with expertise in bone sarcomas, or through centralized revision in a referral centre, according to national rules.\n2. Age ≥ 4 years old (when able to swallow tablet) ; no upper age limit\n3. First line systemic and local treatment of primary tumour (and metastasis when present) for localised or metastatic osteosarcoma must have been completed according to national guidelines (Mifamurtide is allowed according to centre's practices)\n4. Recovery to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5 Grade 0 or 1 level or recovery to baseline health status preceding the prior treatment from any previous drug\u002Fprocedure related toxicity (except alopecia, anaemia, and hypothyroidism)\n5. Performance status \\\u003C 2 for patient adult, or \\>70 using Karnofsky or Lansky performance scores.\n6. Interval between the last treatment either chemotherapy administration or surgical procedures or radiotherapy or thermoablation, (whichever occurred last) and the date of randomisation should be at least 4 weeks but no longer than 2 months;\n7. Disease in complete remission or with residual persistent stable disease according to RECIST criteria before randomisation (please refer 7.3.4 for the definition of the residual persistent stable disease )\n8. Patient fit to undergo protocol treatment and follow-up\n9. Adequate cardiac function: Left Ventricular Ejection Fraction (LVEF) ≥50% and\u002For fractional shortening (FS) \\>28% at baseline as determined by echocardiography or multigated acquisition (MUGA) scan (performed only if echocardiography is not feasible)\n10. Adequately controlled blood pressure (BP) with or without antihypertensive medications: BP 95th percentile for sex, age and height\u002Flength at screening (as per NHLBI (National Heart, Lung and Blood Institute) guidelines) and no change in antihypertensive medications within 1 week prior to start of treatment (C1D1). Patients aged \\>18 years should have a BP ≤150\u002F90 mmHg at screening and no change in antihypertensive therapy within 1 week prior to C1D1\n11. Screening laboratory values must meet the following criteria (according to CTCAE v5) and should be obtained within 7 days prior to randomisation\n\n    * Absolute neutrophil count ≥ 1 x 109\u002FL\n    * Platelets ≥ 100 x 109\u002FL\n    * Haemoglobin ≥ 8.0 g\u002FdL (a hemoglobin of less than 8.0 g\u002Fdl is acceptable if it is corrected by growth factor or transfusion before C1D1)\n    * Serum creatinine ≤ 1.5 x ULN or based on age\u002Fgender. If serum creatinine is greater than maximum serum creatinine for age\u002Fgender as described, then creatinine clearance (or radioisotope Glomerular Filtration Rate (GFR)) must be \\>60 ml\u002Fmin\u002F1.73 m2\n    * Urine dipstick \\\u003C 2+ for proteinuria. Patients who have ≥2+ proteinuria on dipstick urinalysis should undergo a spot Protein\u002FCreatinine ratio test that should be grade 2 (less or equal) per CTCAE v5.0\n    * No clinical evidence of nephrotic syndrome\n    * Alanine Aminotransferase\u002FAspartate Aminotransferase (ALT\u002FAST) ≤ 2.5 x Upper limit of normal (ULN) in the absence of liver metastases or ≤ 5.0 x ULN in the presence of liver metastases\n    * Total bilirubin ≤ 1.5 x ULN (except Gilbert Syndrome: \\\u003C 3.0 mg\u002FdL) or ≤ 5.0 x ULN in the presence of liver metastases\n    * Alkaline phosphatase (PAL) ≤2.5 x ULN (≤5 x ULN in patient with liver involvement of their cancer). If Alkaline phosphatase \\> 2.5 ULN, Gamma-Glutamyl Transferase GGT tests must be performed; GGT \\\u003C 1.5 x ULN\n    * Lipase ≤1.5 x ULN\n    * INR (International Normalized Ratio) \u002FPTT (Partial Thromboplatin Time) ≤1.5 x ULN\n12. Patients who are therapeutically treated with an agent such as warfarin or heparin\u002F Low-molecular-weight heparin (LMWH) will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists.\n13. Women of childbearing potential or young women of childbearing potential and who started their puberty (menarche) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of Human Chorionic Gonadotropin (HCG)) done within 7 days prior to randomisation.\n14. Effective methods of contraception should be used by male and female patients and their partners during therapy, and for at least 4 months after completing therapy. Because oral contraceptives might not be considered as \"effective methods of contraception\", they should be used together with another method, such as a barrier method, according to age and gynaecologist advice\n15. Provision of dated and signed written informed consent from patients or for minor, from their parents\u002F legal representatives, for the randomised trial prior to any study specific procedures, sampling and analyses..\n16. Affiliation to a social insurance or equivalent regimen (if required in the country).","ALL","4 Years",{"count":20,"type":21},530,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This clinical study is the initiative of the FOSTER (Fight OsteoSarcoma Through European Research) consortium and Gustave Roussy, which is the sponsor. Its aim is to evaluate the biology of tumour in greater depth by collecting samples of the tumour during the biopsy at diagnosis, and blood samples. This study is a platform study that evolves over time. This means that it allows for the evaluation of several treatments or therapeutic strategies within a single clinical trial, which can be modified and adapted over time.\n\nThe FOSTER evolving study platform aim to implement a comprehensive strategy of clinical, biological, radiological, therapeutic integrated research from diagnosis to relapse, with the aim to improve survival of osteosarcoma patients of all age, through randomised therapeutic questions at different phase of treatment from diagnosis to relapse. The platform study makes it possible to evaluate several treatments for the same disease, on an ongoing basis, using a main protocol with adaptable arms.\n\nThe FOSTER-CabOS trial (part 2 of FOSTER study) is a European Phase III clinical study . It assesses the efficacy of cabozantinib, a tyrosine kinase inhibitor, as a maintenance therapy post-standard treatment in osteosarcoma patients. The trial is randomized against Best Supportive Care to determine the effectiveness of cabozantinib in improving event-free survival. This maintenance therapy aims to prevent relapse among patients who have already received standard treatment for osteosarcoma.",[27,28,29,30,31],"Osteosarcoma","Pediatric Osteosarcoma","Osteosarcoma in Children","Osteosarcoma in Adolescents and Young Adults","Osteosarcoma Metastatic",[33,15,34,35],"platform trial","osteosarcoma patients","Paediatrics and adults patients with high-grade osteosarcoma","RECRUITING","2026-10-06",{"date":39,"type":40},"2026-10-13","ACTUAL",{"date":42,"type":21},"2026-10",{"date":44,"type":21},"2036-01",{"name":46,"class":47},"Gustave Roussy, Cancer Campus, Grand Paris","OTHER",77,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100625927","phase-2-evaluating-efficacy-of-b7-h3-car-t-cells-administered-at-the-end-of-upfront-map-chemotherapy-in-patients-with-newly-diagnosed-high-risk-osteosarcoma-100625927","NCT07428993","Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma","A Phase II Study Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma","Inclusion Criteria:\n\n1. Participant and\u002For legally authorized representative has signed the Informed Consent Form for this study\n2. Prior cancer therapy:\n\n   * Regimen A only: Completed all planned cycles of consolidation therapy between 14-28 days prior.\n   * Regimen B only: has completed all planned cycles of consolidation chemotherapy at least 14 days prior and if clinically indicated, participant has undergone pulmonary metastasectomy. They must have recovered from any surgical complications with no ongoing sequelae of category 2 or higher by the Clavien-Dindo classification system and less than 6 weeks must have passed from time of pulmonary metastasectomy.\n3. No evidence of progressive disease since enrolled on study\n4. Lansky performance status score of ≥ 50 for participants \\\u003C16 years of age or Karnofsky score ≥ 50 for participants ≥ 16 years. Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for purposes of assessing performance status\n5. Adequate organ function as indicated by:\n\n   * Renal: Serum creatinine ≤ 1.5 X the upper limit of normal (ULN) based on enrollment eligibility table.\n   * Hepatic: Total bilirubin ≤ 3 times ULN for age OR conjugated bilirubin ≤ 2 mg\u002FdL AND ALT (SGPT) ≤ 5 times ULN\n   * Cardiac: Shortening fraction ≥ 28% OR ejection fraction ≥ 50% as measured by echocardiogram\n   * Respiratory: Oxygen saturation ≥ 90% on room air without supplemental oxygen or mechanical ventilation\n6. Laboratory values meet the following criteria:\n\n   * Absolute Neutrophil Count (ANC) ≥ 750 cells\u002FuL\n   * Platelet Count of ≥ 75,000 (can be transfused)\n   * Hemoglobin ≥ 7 g\u002FdL (can be transfused)\n7. Participant is ≥ 7 days from receiving supra-physiologic dosing of systemic (IV or PO) corticosteroids. Glucocorticosteroid physiologic replacement therapy for management of adrenal insufficiency is allowed.\n8. Participant and\u002For legally authorized representative has signed the Informed Consent Form for the treatment phase of this study.\n\nExclusion Criteria:\n\n1. Major surgical adverse event related to the primary tumor local control defined as Clavien-Dindo category 3 requiring ongoing wound care.\n2. Evidence of clinically significant encephalopathy\u002Fnew focal neurologic deficits.\n3. Presence of active severe infection, defined as:\n\n   * positive blood culture within 48 hours of enrollment, OR\n   * fever above 38.2° C, AND clinical signs of infection within 48 hours of enrollment\n4. Participant has received prior disease-directed therapy other than 1st line therapy with methotrexate, an anthracycline, and a platinum and local control surgery\n\n   • Regimen B only - okay to have undergone initial pulmonary metastasectomy\n5. Pregnant or breastfeeding\n6. Presence of any condition that, in the opinion of the investigator, would prohibit the participant from undergoing treatment under this protocol","21 Years",{"count":58,"type":21},41,[60],"PHASE2","The purpose of this study is to assess the safety, feasibility, and effectiveness of a consolidative B7-H3 CAR T cell therapy in patients with newly diagnosed high-risk osteosarcoma who have undergone upfront standard chemotherapy.\n\nPrimary Objectives:\n\n\\- To evaluate 1-year RFS from the time of SJCARB7H3-41BBL infusion for patients with newly diagnosed metastatic osteosarcoma who received standard chemotherapy.\n\nSecondary Objectives:\n\n* To evaluate the OS from time of SJCARB7H3-41BBL infusion for patients with newly diagnosed metastatic osteosarcoma who received standard chemotherapy.\n* To evaluate the feasibility of delivering SJCARB7H3-41BBL at the end of standard therapy in patients with newly diagnosed metastatic osteosarcoma.\n* To describe the safety of autologous SJCARB7H3-41BBL therapy when delivered at the end of standard therapy in patients with newly diagnosed metastatic osteosarcoma.",[28],[27],"2026-08-28",{"date":66,"type":40},"2026-09-01",{"date":68,"type":21},"2026-09",{"date":70,"type":21},"2035-12",{"name":72,"class":47},"St. Jude Children's Research Hospital",1]